Overview

DX-8951f in Treating Patients With Biliary Cancer

Status:
Completed

Trial end date:
2005-04-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DX-8951f in treating patients who have biliary cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Daiichi Sankyo Inc.
Daiichi Sankyo, Inc.

Treatments:

Exatecan